Health Catalyst (HCAT Quick QuoteHCAT - Free Report) reported $74.68 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 6.2%. EPS of $0.08 for the same period compares to $0.04 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $73.61 million, representing a surprise of +1.45%. The company delivered an EPS surprise of -14.26%, with the consensus EPS estimate being $0.09.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Professional services: $22.81 million versus $22.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -18.6% change.
• Revenue- Technology: $51.87 million versus $50.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.5% change.
• Adjusted Gross Profit- Professional Services: $4.61 million compared to the $4.68 million average estimate based on two analysts.
• Adjusted Gross Profit- Technology: $35.35 million versus $34.51 million estimated by two analysts on average.

View all Key Company Metrics for Health Catalyst here>>>

Shares of Health Catalyst have returned -6.5% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.